DK1663185T3 - Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab - Google Patents

Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab

Info

Publication number
DK1663185T3
DK1663185T3 DK04765458T DK04765458T DK1663185T3 DK 1663185 T3 DK1663185 T3 DK 1663185T3 DK 04765458 T DK04765458 T DK 04765458T DK 04765458 T DK04765458 T DK 04765458T DK 1663185 T3 DK1663185 T3 DK 1663185T3
Authority
DK
Denmark
Prior art keywords
inflammation
immune
induced
prevention
treatment
Prior art date
Application number
DK04765458T
Other languages
Danish (da)
English (en)
Inventor
Thomas Wilckens
Ariane Volkmann Dr
Original Assignee
Onepharm Res & Dev Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onepharm Res & Dev Gmbh filed Critical Onepharm Res & Dev Gmbh
Application granted granted Critical
Publication of DK1663185T3 publication Critical patent/DK1663185T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Chemical And Physical Treatments For Wood And The Like (AREA)
  • Veneer Processing And Manufacture Of Plywood (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04765458T 2003-09-22 2004-09-21 Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab DK1663185T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50471703P 2003-09-22 2003-09-22
PCT/EP2004/010582 WO2005027882A1 (fr) 2003-09-22 2004-09-21 Prevention et traitement de la perte osseuse induite par inflammation et/ou immuno-mediee

Publications (1)

Publication Number Publication Date
DK1663185T3 true DK1663185T3 (da) 2009-04-06

Family

ID=34375537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04765458T DK1663185T3 (da) 2003-09-22 2004-09-21 Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab

Country Status (15)

Country Link
US (2) US20100087413A1 (fr)
EP (2) EP1663185B1 (fr)
JP (1) JP2007533625A (fr)
AT (1) ATE416761T1 (fr)
AU (1) AU2004273610B2 (fr)
CA (1) CA2539741A1 (fr)
CY (1) CY1111246T1 (fr)
DE (1) DE602004018338D1 (fr)
DK (1) DK1663185T3 (fr)
ES (1) ES2317029T3 (fr)
NZ (1) NZ546062A (fr)
PL (1) PL1663185T3 (fr)
PT (1) PT1663185E (fr)
SI (1) SI1663185T1 (fr)
WO (1) WO2005027882A1 (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006026619A2 (fr) * 2004-08-30 2006-03-09 Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Methodes et compositions ayant trait a l'inhibition de virus utilisant des inhibiteurs de rnase h
JP5140577B2 (ja) 2005-03-31 2013-02-06 タケダ カリフォルニア インコーポレイテッド ヒドロキシステロイドデヒドロゲナーゼ阻害剤
DE102005026231A1 (de) * 2005-06-07 2006-12-14 Origenis Ag Peptid-Deformylase (PDF) Inhibitoren 3
DK1864668T3 (da) * 2006-06-01 2013-03-04 Novagali Pharma Sa Anvendelse af prodrug til okulær, intravitreal administration
ES2385505T3 (es) * 2006-07-06 2012-07-25 Glaxo Group Limited N-fenilmetil-5-oxo-prolina-2-amidas sustituidas como antagonistas del receptor P2X7 y métodos de uso
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
KR101022809B1 (ko) * 2008-02-05 2011-03-17 재단법인서울대학교산학협력재단 면역조절에 의한 캔디다알비칸스 기인성 질환의 치료
JP5637562B2 (ja) * 2008-09-25 2014-12-10 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2010088414A2 (fr) * 2009-01-28 2010-08-05 Emory University Potentialisateurs du récepteur nmda, sélectifs pour des sous-unités, et destinés au traitement d'états neurologiques
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
JP2012041291A (ja) * 2010-08-18 2012-03-01 Institute Of Physical & Chemical Research 歯周病の治療または予防剤
ITRM20100614A1 (it) * 2010-11-24 2012-05-25 D M G Italia S R L Preparazioni farmaceutiche dell acido 18 beta glicirretico e/o di suoi derivati per infiltrazioni intrarticolari per il trattamento delle artropatie infiammatorie
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104321325B (zh) 2012-05-24 2016-11-16 诺华股份有限公司 吡咯并吡咯烷酮化合物
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014115080A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés pyrazolo[3,4-d]pyrimidinone utilisés en tant qu'inhibiteurs de l'interaction p53/mdm2
WO2014115077A1 (fr) 2013-01-22 2014-07-31 Novartis Ag Composés de purinone substitués
EP3004109A1 (fr) 2013-05-27 2016-04-13 Novartis AG Dérivés imidazopyrrolidinone et leur utilisation dans le traitement de maladies
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
MX2015016421A (es) 2013-05-28 2016-03-03 Novartis Ag Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2016006667A (es) 2013-11-21 2016-07-26 Novartis Ag Derivados de pirrolo-pirrolona y su uso como inhibidores.
CN104873521A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其应用
CN104873520A (zh) * 2014-02-27 2015-09-02 天津药物研究院 一种11β-羟基类固醇脱氢酶抑制剂、药用组合物及其用途
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (fr) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. Composition pharmaceutique d'hormone stéroïde
EA202090438A1 (ru) * 2017-08-04 2020-06-15 Арделикс, Инк. Производные глицерретиновой кислоты для лечения гиперкалиемии
GB201805100D0 (en) * 2018-03-28 2018-05-09 Benevolentai Bio Ltd Treatment of sarcopenic diseases
MX2021009491A (es) * 2019-02-07 2021-09-08 Ardelyx Inc Compuestos y metodos para tratar la hiperpotasemia.

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3262851A (en) * 1958-06-26 1966-07-26 Biorex Laboratories Ltd Pharmacological compositions containing glycyrrhetinic acid derivative
DE2050072C3 (de) * 1970-10-12 1975-01-30 Inverni Della Beffa S.P.A., Mailand (Italien) Aluminium-tri-3-acetyl-18 betaglycyrrthetinat, Verfahren zu seiner Herstellung und dieses enthaltende pharmazeutische Zubereitungen
US3934027A (en) * 1973-05-03 1976-01-20 Pfizer Inc. 18β-Glycyrrhetinic acid amides useful as antiulcer agents
EP0496520A1 (fr) * 1991-01-22 1992-07-29 Merck & Co. Inc. Agents actifs sur les os
GB2261672A (en) * 1991-11-18 1993-05-26 Michael Braden The use of biomaterials for tissue repair
JPH07291857A (ja) * 1994-04-27 1995-11-07 Suntory Ltd グリチルレチン酸化合物を有効成分とする骨疾患の予防及び治療剤
DE19951970A1 (de) * 1999-10-28 2001-05-03 Bionetworks Gmbh Arzneimittel für die Toleranzinduktion
US20050048007A1 (en) * 2000-11-02 2005-03-03 Inobys Ltd. Plaque reducing composition
GB0105772D0 (en) 2001-03-08 2001-04-25 Sterix Ltd Use
GB0107383D0 (en) * 2001-03-23 2001-05-16 Univ Edinburgh Lipid profile modulation
IL160630A0 (en) 2001-11-22 2004-07-25 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CN1564816A (zh) 2001-11-22 2005-01-12 比奥维特罗姆股份公司 11－β－羟基类固醇脱氢酶1型抑制剂
US7329683B2 (en) 2002-02-01 2008-02-12 Merck & Co., Inc. 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
AR040241A1 (es) 2002-06-10 2005-03-23 Merck & Co Inc Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia
EP2380900A1 (fr) 2002-09-23 2011-10-26 E. I. du Pont de Nemours and Company Isolement et utilisation de récepteurs de la ryanodine
JO2397B1 (en) 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2004056744A1 (fr) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides utilises comme inhibiteurs de la hydroxysteroide deshydrogenase
US20030148349A1 (en) * 2003-01-03 2003-08-07 Shyam Ramakrishnan Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PT1663185E (pt) 2009-02-16
ATE416761T1 (de) 2008-12-15
US20100087413A1 (en) 2010-04-08
EP1663185B1 (fr) 2008-12-10
EP1663185A1 (fr) 2006-06-07
CA2539741A1 (fr) 2005-03-31
EP2036548A1 (fr) 2009-03-18
PL1663185T3 (pl) 2009-06-30
JP2007533625A (ja) 2007-11-22
AU2004273610A1 (en) 2005-03-31
NZ546062A (en) 2009-09-25
CY1111246T1 (el) 2015-06-11
AU2004273610B2 (en) 2010-07-01
ES2317029T3 (es) 2009-04-16
SI1663185T1 (sl) 2009-04-30
US20110275584A1 (en) 2011-11-10
WO2005027882A1 (fr) 2005-03-31
DE602004018338D1 (de) 2009-01-22

Similar Documents

Publication Publication Date Title
DK1663185T3 (da) Forebyggelse og behandling af inflammationsinduceret og/eller immun-medieret knogletab
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60312017D1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE503461T1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
BR9914044A (pt) ésteres tetrahidropirido
NO20035474D0 (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
ATE274330T1 (de) Gleitschutz fur einen gehäusekopf medizinischer instrumente
BR0116052A (pt) imidazoquinolinas substituìdas por éter arìlico
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
BR0214750A (pt) Imidazoquinolinas tioéter substituìdas
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
BR0309581A (pt) Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c
DK1506041T3 (da) Inbandronsyre til behandling og forebyggelse af osteoporose
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
IT1318649B1 (it) Composizioni farmaceutiche per il trattamento di mucositi e stomatiti.
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
PA8466101A1 (es) Agentes terapeuticos
ATE277026T1 (de) Naphthylverbindungen, zusammensetzungen und verfahren
DK1372669T3 (da) Bisphosphonatholding sammensætning til forebyggelse og/eller behandling af metaboliske knoglesygdomme, fremgangsmåde til fremstilling af sådanne sammensætninger og anvendelse deraf
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2392838B (en) Calcium L-threonate for preventing or treating cartilage related diseases
AR029394A1 (es) Arilcetonas substituidas, procedimientos para su preparacion, benzoilcetonas utiles en dicho procedimiento, empleo de estos compuestos para la lucha contra las plantas indeseables, y composiciones
DE60217720D1 (de) Kurkumin-zusammensetzung zur heilung von dickdarmpolypen